MedTrace Logo

A Trial of HRS-9813 in Healthy Subjects

NCT06821464 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-05-07

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Conditions

  • Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis

Interventions

DRUG

HRS-9813

Initial dose to planned dose（low dose）

DRUG

HRS-9813

Initial dose to planned dose（high dose）

Sponsors & Collaborators

  • Guangdong Hengrui Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2025-06-30
Completion
2025-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06821464 on ClinicalTrials.gov